ProKidney (NASDAQ:PROK) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

ProKidney (NASDAQ:PROK) posted its quarterly earnings results on Monday. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03), Zacks reports. The business had revenue of $0.08 million for the quarter.

ProKidney Stock Up 5.7 %

ProKidney stock opened at $1.04 on Tuesday. ProKidney has a 52-week low of $0.94 and a 52-week high of $4.44. The company has a market cap of $303.33 million, a price-to-earnings ratio of -1.89 and a beta of 1.38. The firm’s fifty day moving average is $1.48 and its 200 day moving average is $1.77.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.